ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

AMLX vs VKTX // FORWARD P/E MULTIPLE

Amylyx Pharmaceuticals Inc. (NASDAQ) VS. Viking Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: AMLX 3 — VKTX 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AMLX VS. VKTX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC AMLX VKTX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -3.43% -8.25% +4.82 AMLX /fcf-yield <GO>
Operating Margin — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) — 15.40% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 24.02 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 5/9 -2.00 VKTX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 51.9 48.3 +3.60 AMLX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 0.91 — TIE /macro-sensitivity <GO>
Forward P/E Multiple ACTIVE — 35.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $3.62B $3.48B $141.9M AMLX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR AMLX REV VKTX REV AMLX GROSS % VKTX GROSS % AMLX FCF VKTX FCF
FY 2025 $429.2M $1.10B — — -$123.5M -$278.7M
FY 2024 $87.4M $422.6M 93.2% — -$167.8M -$87.8M
FY 2023 $380.8M $282.3M — — $11.9M -$73.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AMLX // BETA —
VKTX // BETA 0.91